A treatment that’s already made headlines for psoriasis is now approved for psoriatic arthritis too.
Cosentyx (secukinumab), a biologic drug made by Novartis, has won approval from the U.S. Food and Drug Administration for the treatment of psoriatic arthritis. The drug has been approved as a treatment for chronic plaque psoriasis since January 2015.
In randomized, placebo-controlled clinical trials, Cosentyx delivered relief from both skin and joint symptoms. According to the data, about half of the patients in Phase III trials saw at least a 20 percent improvement in their psoriatic arthritis, compared to about 15 percent of patients on placebo.
About two-thirds of patients in the same trials experienced at least a 75 percent improvement in their skin psoriasis.
In other clinical trials for the drug, more than half of patients taking Cosentyx experienced clear or almost clear skin, while the majority experienced significant improvement.
The most common side effects experienced by patients on Cosentyx included the common cold and headache, according to trial data.
Cosentyx targets interleukin-17A, which is a protein, or cytokine, that triggers inflammation.
For more information, visit Cosentyx.
Driving discovery, creating community
For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.